Oragenics faces NYSE American listing deficiency as ONP-002 trial advances
AI Summary- Oragenics advanced ONP-002 through a Phase IIa feasibility trial in Australia.
- Nine participants have been dosed across three active Australian clinical sites.
- Oragenics received a 45-day deadline to submit a NYSE American compliance plan.